Document:

<PAGE>

                                                                     Exhibit 4.9

[*] =Certain confidential information contained in this exhibit, marked by
brackets with asterisks, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.

             AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT

THIS AMENDMENT to the License, Development and Supply Agreement dated May 9,
2002, ("Agreement") is made effective the 20th day of December 2002 by and
between IMI International Medical Innovations Inc., a Canadian corporation,
having its principal place of business at Suite 300, 4211 Yonge Street, Toronto,
Ontario, M2P 2A9, Canada ("IMI") and McNeil PDI Inc., a Canadian corporation,
having its principal place of business at 768 Herbert Street, Desbiens, Quebec,
Canada (acting through its McNEIL Consumer Healthcare division on behalf of
McNeil PDI Inc.) ("MCNEIL").

Whereas:

A. MCNEIL has determined, through its market research, that the Laboratory Field
is the first field to be pursued in Canada by McNeil.
B. IMI desires that MCNEIL
take an expanded roll in advancing IMI's skin cholesterol measurement
technology.

                                    ARTICLE I
                                   DEFINITIONS

Section 1.9.3 shall be amended to read:

         1.9.3 "Laboratory Field" shall mean the field of diagnosing, predicting
         and monitoring of cardiac risk utilizing systems that are approved by
         the applicable governmental regulatory authorities for use under the
         supervision of trained medical personnel and/or trained healthcare
         workers and that are operated in an outpatient clinic, medical
         laboratory, patient collection center associated with a laboratory,
         hospital laboratory or similar venue providing laboratory services, and
         for clarification, the parties agree that Laboratory Field includes the
         "Insurance Laboratory Field", which shall mean the field of diagnosing,
         predicting and monitoring of cardiac risk utilizing systems that are
         approved by the

<PAGE>

         applicable governmental regulatory authorities for use under the
         supervision of trained medical personnel and/or trained healthcare
         workers and that are operated by a service provider, or in a venue
         providing laboratory services, provided that such field shall be solely
         related to the analysis of the cardiac health of an insurance
         applicant;

Section 1.11 shall be amended to read:
1.11     "Licensed Fields" shall mean the Consumer, Nutraceutical, Professional,
Laboratory and Other Medical Fields defined above.

Section 1.20 shall be amended to read:
1.20     "Territory" shall mean:
         a) Canada and its territories and possessions for Fields outside the
         Insurance Laboratory Field (as defined above), and
         b) solely in relation to the Insurance Laboratory Field, Territory
         shall also include the "Insurance Territory", which, in addition to
         Canada and its territories and possessions, shall mean Mexico and the
         United States and shall include their territories and possessions.

                                   ARTICLE III
                 LICENSE GRANTS, EXCLUSIVITY, AND FUTURE RIGHTS

Section 3.1 shall be amended to read:
3.1 For the term of this Agreement, IMI hereby grants to MCNEIL the exclusive
right and license in the Licensed Fields under the Licensed Patents and Licensed
Know-How to use, sell and have sold products, processes and/or apparatus
embodying the Licensed Patents and/or Licensed Know-How in the Territory. MCNEIL
may grant sublicenses of such rights, subject to IMI's prior written approval.
IMI's approval will be deemed granted unless it provides written objection
within fifteen (15) Business Days of MCNEIL's written notification of its desire
to grant a particular sublicense. MCNEIL shall not use or sublicense any rights
granted hereunder or offer any Licensed Products to any person whom MCNEIL has
reason to believe will use such rights or Licensed Products outside of the
Territory. For greater certainty and clarification, the parties agree and
acknowledge that the foregoing grant includes the grant of the enumerated rights
and licenses

                                       -2-

<PAGE>

in the Insurance Territory solely in respect of the Insurance Laboratory Field.
MCNEIL shall, in respect of any person to whom it sells Licensed Products for
use in the Insurance Territory outside of Canada, obtain a written
acknowledgement and agreement from such person in the form attached as Schedule
"M" hereto.

                                  ARTICLE XVII
                              TERM AND TERMINATION

Section 17.3 shall be amended to read:
17.3 MCNEIL may terminate this Agreement at any time prior to MCNEIL'S first
commercial sale of Licensed Product in the Territory upon thirty (30) days prior
written notice to IMI and thereafter, upon ninety (90) days prior written notice
to IMI. This Agreement may be terminated by MCNEIL on a country by country
basis, provided that if MCNEIL terminates this Agreement insofar as it concerns
Canada and its territories and possessions this Agreement shall also be deemed
to be terminated in the Insurance Territory.

Section 17.4.1 shall be amended by inserting the words "IMI provides MCNEIL with
Licensed Product conforming to specifications which the parties shall agree
upon, acting reasonably, prior to January 31, 2003 and" after "Professional
Field if".

Section 17.4.1(i) shall be amended by deleting the words "the first anniversary
of the Effective Date" and replacing such words with "the end of the 6th month
following the first shipment of any Licensed Product from IMI to MCNEIL which
conforms to the foregoing specifications".

Section 17.4.1(ii) shall be amended by deleting the words "the first anniversary
of the Effective Date" and replacing such words with "the first shipment of
Licensed Product from IMI to MCNEIL".

Notwithstanding the three immediately preceding paragraphs, if for any reason
the parties are unable to agree, on or prior to February 15, 2003, upon the
specifications which Section 17.4.1, as amended, contemplates that the parties
shall agree upon prior to January 31, 2003, then the

                                       -3-

<PAGE>

foregoing amendments to Section 17.4.1, 17.4.1(i) and 17.4.1(ii) shall be
considered to have never been made and the Agreement shall be deemed to be
amended to provide that the original terms and conditions of such provisions
shall continue to apply.

Section 17.4.4(i) shall be amended by deleting the words "the option
contemplated in Section 3.2 is exercised" and replacing such words with "IMI
provides MCNEIL with Licensed Product conforming to specifications which the
parties shall agree upon, acting reasonably, prior to January 31, 2003)" and by
deleting the number $***** and replacing such number with $***** and adding the
words ", including at least $***** in Net Sales in Canada relating to the
Laboratory Field" after the words "in the Territory".

Notwithstanding the immediately preceding paragraph, if for any reason the
parties are unable to agree, on or prior to February 15, 2003, upon the
specifications which Section 17.4.4(i), as amended, contemplates that the
parties shall agree upon prior to January 31, 2003, then (a) the foregoing
amendments to Section 17.4.4(i) shall be considered to have never been made and
(b) the Agreement shall be deemed to be amended to (1) delete the words "the
anniversary of the date on which the option contemplated in Section 3.2 is
exercised" and (2) replace such words with "December 20 commencing in 2003 (and
December 20 in succeeding years)".

                                  ARTICLE XIII
                            MISCELLANEOUS PROVISIONS

Section 18.1 shall be amended to read:
18.1 The rights and obligations of IMI and MCNEIL under this Agreement are
personal thereto and neither party shall have the right to sublicense, assign,
transfer or delegate, in whole or in part, any of its rights or obligations
hereunder to any third party without the prior written consent of the other
party except that either party may assign this Agreement to any Affiliate
provided that the assignor guarantees all of the covenants and obligations of
such Affiliate arising pursuant to such assignment and except that, solely for
the Insurance Laboratory Field, MCNEIL may assign, transfer or delegate, in
whole or in part, any of its rights or obligations under this Agreement to any

                                       -4-

<PAGE>

Affiliate provided that the MCNEIL guarantees all of the covenants and
obligations of such Affiliate arising pursuant to such assignment, transfer or
delegation.

                   OTHER PROVISIONS OF THIS AMENDING AGREEMENT

(a) Contemporaneously with the execution and delivery of this Amendment, MCNEIL
is delivering to IMI a cheque or bank draft in the amount of $100,000 pursuant
to the exercise by MCNEIL of its option to acquire rights in the Laboratory
Field as contemplated in section 3.2 of the Agreement.

(b) In all other respects, the terms and conditions of the Agreement shall
remain in full force and effect, unamended.

(c) The provisions of sections 18.7, 18.9 and 18.10 shall apply, mutatis
mutandis, to this Amendment.

(d) The Agreement shall be amended by adding Appendix "M" hereto as a
corresponding Appendix thereto.

IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the day
and year first written above.

McNEIL PDI INC.

(acting through its McNEIL Consumer Healthcare division on behalf of McNeil PDI
Inc.)

By:   /s/ Jerry Norsky
    ------------------------
      Name:
      Title:
      Authorized Signing Officer

IMI INTERNATIONAL MEDICAL INNOVATIONS INC.

By:   /s/ Brent Norton
    ------------------------
      Name:
      Title:
      Authorized Signing Officer

                                       -5-

<PAGE>

                                  Appendix "M"

To:      McNEIL PDI INC.  (or the other Affiliates of McNeil who will effect
         the Sale}
And to:  IMI INTERNATIONAL MEDICAL INNOVATIONS INC.

In consideration of the sale or other provision from time to time by _________
{Note to draft: McNEIL or the other ------------- Affiliates of McNeil who will
effect the Sale} to the undersigned of a cardiac risk predictor that measures
skin cholesterol marketed under the name o (the "Product"), and for other
good and valuable consideration, the undersigned hereby acknowledges and agrees
that:

1. It is acquiring the Product for its own purposes only, and will not
sell, provide or otherwise distribute the Product to any other person (other
than to insurance brokers and agents for the purposes of collecting samples from
policy holders for delivery to the undersigned in connection with the analysis
to be conducted by the undersigned of such samples)

2. It will use the Product solely for the purpose of diagnosing, predicting and
monitoring of cardiac risk utilizing systems solely related to the analysis of
the cardiac health of an insurance applicant and for no other purposes.

Dated this ________ day of _______________, 200__.

.........................................
{Name of Entity}

by: ____________________________________
         Name:
         Title:
         Authorized Signing Officer

                                       -6-Form of Restricted Stock Agreement between TECO Energy, Inc. & certain officers

Exhibit 10.27 
 
TECO ENERGY, INC. 
1996 EQUITY INCENTIVE PLAN 
 
Restricted Stock Agreement 
 
TECO Energy, Inc. (the “Company”) and
                         (the “Grantee”) have entered into this Restricted Stock Agreement (the
“Agreement”) dated January 28, 2003 under the Company’s 1996 Equity Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein have the meanings given to them in the Plan. 
 
1. Grant of Restricted Stock. Pursuant to the Plan and
subject to the terms and conditions set forth in this Agreement, the Company hereby grants, issues and delivers to the Grantee          shares of its Common Stock (the “Restricted
Stock”). 
 
2. Restrictions on
Stock. Until the restrictions terminate under Section 3, unless otherwise determined by the Committee: 
 
(a) the Restricted Stock may not be sold, assigned, pledged or transferred by the Grantee; and 
 
(b) all shares of Restricted Stock will be
forfeited and returned to the Company if the Grantee ceases to be an employee of the Company or any business entity in which the Company owns directly or indirectly 50% or more of the total voting power or has a significant financial interest as
determined by the Committee (an “Affiliate”). 
 
3. Termination of Restrictions. The restrictions on all shares of Restricted Stock will terminate on the earliest to occur of the following events: 
 
(a) the Grantee’s death; 
 
(b) the termination of Grantee’s employment with the Company or any Affiliate because of
a disability that would entitle the Grantee to benefits under the long-term disability benefits program of the Company for which the Grantee is eligible, as determined by the Committee; 
 
(c) the termination by the Company or any Affiliate of Grantee’s employment other than
for Cause as determined by the Committee. “Cause” means (i) willful and continued failure of the Grantee to substantially perform his duties with the Company or such Affiliate (other than by reason of physical or mental illness) after
written demand specifically identifying such failure is given to the Grantee by the Company, or (ii) willful conduct by the Grantee that is demonstrably and materially injurious to the Company. For purposes of this subsection, “willful”
conduct requires an act, or failure to act, that is not in good faith and that is without reasonable belief that the action or omission was in the best interest of the Company or the Affiliate; 
 
 

1 

Exhibit 10.27 
 
(d) upon a resignation of employment in which the Committee determines in its sole discretion
that the removal of restrictions is appropriate; 
 
(e) upon a Change in Control. For purposes of this Agreement, a “Change in Control” means a change in control of the Company of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A
of Regulation 14A promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), whether or not the Company is in fact required to comply therewith; provided, that, without limitation, such a Change in Control
shall be deemed to have occurred if: 
 
(1) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company or a
corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of securities of the Company representing 30% or more of the combined voting power of the Company’s then outstanding securities; 
 
(2) during any period of twenty-four (24) consecutive months (not including any period prior
to the date of this Agreement), individuals who at the beginning of such period constitute the Board of Directors of the Company and any new director (other than a director designated by a person who has entered into an agreement with the Company to
effect a transaction described in subsections (1), (3) or (4) of this Section 3(e)) whose election by the Board of Directors of the Company or nomination for election by the shareholders of the Company was approved by a vote of at least two-thirds
( 2/3) of the directors then still in office who either were directors at the beginning of such period or whose
election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; 
 
(3) the shareholders of the Company approve a merger or consolidation of the Company with any other corporation, other
than (i) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity) at least 50% of the combined voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation or (ii) a merger or consolidation effected to implement a recapitalization of the
Company (or similar transaction) in which no “person” (as defined above) acquires 30% or more of the combined voting power of the Company’s then outstanding securities; or 
 
(4) the shareholders of the Company approve a plan of complete liquidation of the Company or
an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; or 
 
 

2 

Exhibit 10.27 
 
(f) January 29, 2004. 
 
4. Rights as Shareholder. Subject to the restrictions and other limitations and conditions provided in
this Agreement, the Grantee as owner of the Restricted Stock will have all the rights of a shareholder, including but not limited to the right to receive all dividends paid on, and the right to vote, such Restricted Stock. 
 
5. Stock Certificates. Each certificate issued for
shares of Restricted Stock will be registered in the name of the Grantee and deposited by the Grantee, together with a stock power endorsed in blank, with the Company and will bear a legend in substantially the following form: 
 
THE TRANSFERABILITY OF THIS CERTIFICATE AND THE SHARES OF
STOCK REPRESENTED HEREBY ARE SUBJECT TO THE TERMS, CONDITIONS AND RESTRICTIONS (INCLUDING RESTRICTIONS ON TRANSFER AND FORFEITURE PROVISIONS) CONTAINED IN AN AGREEMENT BETWEEN THE REGISTERED OWNER AND TECO ENERGY, INC. A COPY OF SUCH AGREEMENT WILL
BE FURNISHED TO THE HOLDER OF THIS CERTIFICATE UPON WRITTEN REQUEST AND WITHOUT CHARGE. 
 
Upon the termination of the restrictions imposed under this Agreement as to any shares of Restricted Stock deposited with the Company hereunder, the Company will return to the Grantee (or to such
Grantee’s legal representative, beneficiary or heir) certificates, without such legend, for such shares. 
 
6. Adjustment of Terms. In the event of corporate transactions affecting the Company’s outstanding Common Stock, the Committee
will equitably adjust the number and kind of shares subject to this Agreement to the extent provided by the Plan. 
 
7. Notice of Election Under Section 83(b). If the Grantee makes an election under Section 83(b) of the Internal Revenue Code of
1986, as amended, he will provide a copy thereof to the Company within thirty days of the filing of such election with the Internal Revenue Service. 
 
8. Withholding Taxes. The Grantee will pay to the Company, or make provision satisfactory to the Committee for payment of, any
taxes required by law to be withheld in respect of the Restricted Stock no later than the date of the event creating the tax liability. In the Committee’s discretion, such tax obligations may be paid in whole or in part in shares of Common
Stock, including the Restricted Stock, valued at fair market value on the date of delivery. The Company and its Affiliates may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to the
Grantee. 
 
9. The Committee. Any
determination by the Committee under, or interpretation of the terms of, this Agreement or the Plan will be final and binding on the Grantee. 
 
10. Limitation of Rights. The Grantee will have no right to continued employment by virtue of this grant of Restricted Stock.

 

3 

Exhibit 10.27 
 
11. Amendment. The Company may amend, modify or terminate this Agreement, including substituting
another Award of the same or a different type and changing the date of realization, provided that the Grantee’s consent to such action will be required unless the action, taking into account any related action, would not adversely affect the
Grantee. 
 
12. Governing Law. This
Agreement will be governed by and interpreted in accordance with the laws of Florida. 
 

	 TECO ENERGY, INC

	
	 By:
	 	

	 	 	 C.E. Childress
 Chief Human Resources Officer

	
	 	 	

	 	 	 Signature of Grantee

	 	 	 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]